UNSPSC 51284044: Tetracycline metaphosphate

This classification denotes a tetracycline antibiotic with the molecular structure C22H24N2O8.(NA)MOD.(O3P)MOD, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 6B7BK5H33B chemically known as 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo, (4s-(4.alpha.,4a.alpha.,5a.alpha.,6.beta.,12a.alpha.))-, phosphate complex, but more commonly known as tetracycline phosphate complex, which bears US NIH Compound Identifier 16131193.

European Medicines Agency schedules Tetracycline phosphate complex in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04761MIG. Most nations, for tariff and trade purposes, schedule tetracycline metaphosphate under HS 29413000. SMILES:.

UNSPSC 51284044 Tetracycline metaphosphate is a Commodity code with little relevant recent activity in state and local procurement. The code nominally describes a specific pharmaceutical compound, but the recent opportunities posted against it show a substantial mismatch: they solicit naloxone and drug deactivation systems, pharmacy benefit program administration, emergency medical supplies, and generic multi-source pharmaceuticals and OTC products — none of which are tetracycline metaphosphate or closely related compounds. State and local procurement offices appear to have applied the code to a broader pharmaceutical and medical supply category without precision alignment to the commodity's actual scope.

The geographic spread and issuing bodies represented in the opportunities reflect standard state and local health procurement: Seminole County, Florida (naloxone and deactivation systems via IFB), the City of Tampa (emergency medical supplies via ITB with a $700,000 estimated value and a certified Small Local Business Enterprise set-aside with a 5 percent bid discount), the Texas Health and Human Services Commission (pharmacy benefit program strategy via RFI), and the Minnesota Multistate Cooperative Purchasing Alliance (generic pharmaceuticals and OTC products via RFP with response due March 26, 2026). The code shows no consistent pattern of solicitations for tetracycline metaphosphate specifically, and pursuit under this code would require clarification with the issuing agency on whether the posted opportunities reflect actual demand or miscategorization in the state or local procurement system.